Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Sanofi

    NASDAQ: SNY · Real-Time Price · USD
    46.61
    -0.42 (-0.89%)
    At close: Sep 15, 2025, 3:59 PM
    46.50
    -0.23%
    After-hours: Sep 15, 2025, 07:39 PM EDT
    -0.89%
    Bid 46.5
    Market Cap 115.54B
    Revenue (ttm) 43.13B
    Net Income (ttm) 9.13B
    EPS (ttm) 3.01
    PE Ratio (ttm) 15.49
    Forward PE 9.74
    Analyst Buy
    Ask 47.29
    Volume 2,560,329
    Avg. Volume (20D) 2,498,806
    Open 47.03
    Previous Close 47.03
    Day's Range 46.53 - 47.13
    52-Week Range 44.73 - 60.12
    Beta 0.44

    About SNY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SNY
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SNY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Sanofi is scheduled to release its earnings on Oct 24, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 week ago
    -9.14%
    Sanofi shares are trading lower following late-sta... Unlock content with Pro Subscription
    1 month ago
    -7.33%
    Sanofi shares are trading lower after the company reported worse-than-expected Q2 financial results.
    news image

    5 days ago · zacks.com

    SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

    Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.

    news image

    1 week ago · seekingalpha.com

    Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

    Sanofi (NASDAQ:SNY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Paul Hudson - CEO & Director Conference Call Participants Sarita Kapila ...

    news image

    1 week ago · fastcompany.com

    Sanofi market value tanks following weak results on eczema drug trials

    Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab...

    news image

    1 week ago · benzinga.com

    Why Is Sanofi Stock Falling Thursday?

    On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fre...

    news image

    1 week ago · zacks.com

    SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

    Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.

    news image

    1 week ago · benzinga.com

    Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

    French drugmaker Sanofi SA SNY stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expecta...

    news image

    1 week ago · investors.com

    Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'

    Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.

    news image

    1 week ago · marketwatch.com

    Sanofi Shares Sink as Experimental Drug Results Disappoint

    Sanofi shares plunged at the market open Thursday as results from a late-stage trial of its experimental drug to treat skin conditions disappointed investors.

    news image

    1 week ago · reuters.com

    Sanofi shares sink over 9% on weak trial results for experimental inflammation drug

    Shares in French drugmaker Sanofi fell more than 9% on Thursday after late-stage trial data for its experimental inflammatory disease drug amlitelimab fell short of Wall Street expectations.

    news image

    1 week ago · wsj.com

    Sanofi's Eczema Drug Candidate Hits Main Goals in Late-Stage Trial

    Amlitelimab showed efficacy in skin clearance and disease severity compared to placebo in a phase 3 study with adolescent and adults with atopic dermatitis.

    Add to Watchlist